In the Claims

Claims 1-37 (Cancelled)

Claim 38 (New): A method for reducing SHIP-1 function in a mammal, comprising administering to the mammal an efficacious amount of an interfering RNA specific for SHIP-1 mRNA, wherein the interfering RNA reduces SHIP-1 expression within the mammal.

Claim 39 (New): The method of claim 38, wherein the mammal is human.

Claim 40 (New): The method of claim 38, wherein the interfering RNA inhibits SHIP-1 expression within natural killer (NK) cells within the mammal, thereby altering NK cell function.

Claim 41 (New): The method of claim 38, wherein said administering comprises administering a vector comprising a polynucleotide encoding the interfering RNA.

Claim 42 (New): The method of claim 41, wherein the vector is complexed with a liposome.

Claim 43 (New): The method of claim 41, wherein the vector is a plasmid.

Claim 44 (New): The method of claim 41, wherein the vector is a viral vector.

Claim 45 (New): The method of claim 38, wherein the mammal has cancer, autoimmune disease, HIV/AIDS, a genetic deficiency, or a combination of any of the foregoing.

Claim 46 (New): A method for suppressing rejection of a transplant in a mammal, comprising administering to the mammal an efficacious amount of an interfering RNA specific for SHIP-1 mRNA, wherein the interfering RNA reduces SHIP-1 expression within the mammal.

Claim 47 (New): The method of claim 46, wherein the transplant is a bone marrow allograft, a solid organ allograft or xenotransplant, or an MHC disparate marrow graft having an MHC disparity of 1, 2, 3 or more allelic mismatches.

Claim 48 (New): The method of claim 46, wherein the mammal has cancer, autoimmune disease, HIV/AIDS, a genetic deficiency, or a combination of any of the foregoing.

Claim 49 (New): The method of claim 46, wherein the mammal is in need of a histo-incompatible organ transplant, and further comprising the step of administering to the mammal an allogeneic bone marrow transplant.

Claim 50 (New): The method of claim 46, wherein the interfering RNA is administered to the mammal prior to the transplant.

Claim 51 (New): The method of claim 46, wherein the interfering RNA is administered to the mammal at the time of the transplant or subsequent to the transplant.

Claim 52 (New): The method of claim 46, wherein the mammal is human.

Claim 53 (New): The method of claim 46, wherein said administering comprises administering a vector comprising a polynucleotide encoding the interfering RNA.

Claim 54 (New): The method of claim 53, wherein the vector is complexed with a liposome.

Claim 55 (New): The method of claim 53, wherein the vector is a plasmid.

Claim 56 (New): The method of claim 53, wherein the vector is a viral vector.

Claim 57 (New): A method for suppressing graft-versus-host disease in a mammal having or in need of a transplant, comprising administering to the mammal an efficacious amount of an interfering RNA specific for SHIP-1 mRNA, in a pharmaceutically acceptable carrier, wherein the interfering RNA reduces SHIP-1 expression within the mammal.

Claim 58 (New): The method of claim 57, wherein the transplant is a bone marrow allograft, a solid organ allograft or xenotransplant, or a MHC disparate marrow graft having an MHC disparity of 1, 2, 3 or more allelic mismatches.

Claim 59 (New): The method of claim 57, wherein the mammal has cancer, autoimmune disease, HIV/AIDS, a genetic deficiency, or a combination of any of the foregoing.

Claim 60 (New): The method of claim 57, wherein the interfering RNA is administered to the mammal prior to the transplant.

Claim 61 (New): The method of claim 57, wherein the interfering RNA is administered to the mammal at the time of the transplant or subsequent to the transplant.

Claim 62 (New): The method of claim 57, wherein the mammal is human.

Claim 63 (New): The method of claim 57, wherein said administering comprises administering a vector comprising a polynucleotide encoding the interfering RNA.

Claim 64 (New): The method of claim 63, wherein the vector is complexed with a liposome.

Claim 65 (New): The method of claim 63, wherein the vector is a plasmid.

Claim 66 (New): The method of claim 63, wherein the vector is a viral vector.

Claim 67 (New): A therapeutic composition comprising an interfering RNA specific for mammalian SHIP-1 mRNA, in a pharmaceutically acceptable carrier.

Claim 68 (New): The therapeutic composition of claim 67, wherein the SHIP-1 mRNA is human SHIP-1 mRNA.

Claim 69 (New): A therapeutic composition comprising a vector in a pharmaceutically acceptable carrier, wherein said vector comprises a polynucleotide encoding an interfering RNA specific for mammalian SHIP-1 mRNA.

Claim 70 (New): The composition of claim 69, wherein the SHIP-1 mRNA is human SHIP-1 mRNA.

Claim 71 (New): The composition of claim 69, wherein the vector is complexed with a liposome.

Claim 72 (New): The composition of claim 69, wherein the vector is a plasmid.

Claim 73 (New): The composition of claim 69, wherein the vector is a viral vector.